FOCL (Edap TMS) EBIT: $-41.2 Mil (TTM As of Mar. 2026)

What is Edap TMS EBIT?

Edap TMS FOCL +1.91% 53 EBIT is $-41.2 Mil as of Mar. 2026. GuruFocus rates FOCL with a GF Score™ of 53/100 and a GF Value™ of $4.52 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Edap TMS's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-7.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-41.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Edap TMS's annualized ROC % for the quarter that ended in Mar. 2026 was -71.54%. Edap TMS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -152.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Edap TMS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -20.30%.

Edap TMS (NAS:FOCL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Edap TMS's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-29.464 * ( 1 - 0% )	/	( (41.609	+	40.756)	/ 2 )
=	-29.464	/	41.1825
=	-71.54 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	78.997	-	17.365	-	( 20.452	-	max(0, 37.141	-	57.164	+	20.452	))
=	41.609

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	72.059	-	18.447	-	( 15.012	-	max(0, 37.508	-	50.364	+	15.012	))
=	40.756

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Edap TMS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-29.464	/	( ( (12.993 + max(7.624, 0))	+	(13.007 + max(5.012, 0)) )	/	2 )
=	-29.464	/	( ( 20.617	+	18.019 )	/	2 )
=	-29.464	/	19.318
=	-152.52 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(21.286	+	12.83	+	1.298)	-	(17.365	+	7.098	+	3.327)
=	7.624

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(19.653	+	13.332	+	1.692)	-	(18.447	+	7.819	+	3.399)
=	5.012

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Edap TMS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-41.211	/	203.002
	=	-20.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edap TMS EBIT Related Terms

Edap TMS EBIT Historical Data

* Premium members only.

The historical data trend for Edap TMS's EBIT can be seen below:

Edap TMS EBIT Chart

Edap TMS Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

1.07

-2.07

-22.44

-20.02

-28.02

Edap TMS Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-6.31	-6.76	-5.78	-21.30	-7.37

FOCL vs ACH, YI, COSM: EBIT Comparison

For the Medical Distribution subindustry, Edap TMS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edap TMS EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Edap TMS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Edap TMS's EV-to-EBIT falls into.

Save Embed

53GF Score

Edap TMS SA FOCL

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Edap TMS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.2 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-41.2 Mil mean?

Edap TMS (FOCL) has a EBIT of $-41.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Edap TMS.

Is Edap TMS's EBIT too high?

Edap TMS's current EBIT is $-41.2 Mil. Overall, Edap TMS has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Edap TMS's EBIT compare to ACH and YI?

Edap TMS's EBIT of $-41.2 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Distribution company?

A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Edap TMS. Edap TMS's current EBIT is $-41.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Edap TMS stock overvalued right now?

Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $5.08 — trading 12.3% above its estimated fair value. The current EBIT is $-41.2 Mil. Edap TMS's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Edap TMS (FOCL), the current EBIT is $-41.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edap TMS (FOCL) Overvalued in 2026?

Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued. The current stock price of $5.08 is trading 12.3% above its estimated GF Value™ of $4.52. GuruFocus considers Edap TMS to be Modestly Overvalued.

Key valuation signals for FOCL:

EBIT: $-41.2 Mil
GF Value™: $4.52 vs. price of $5.08 (12.3% above fair value)
GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edap TMS Business Description

Industry Healthcare Medical Distribution

Comparable Companies ACH YI COSM HKPD VNOV SNYR MCK COR CAH ASX:SIG HSIC SHSE:601607 HKSE:01099 XSWX:GALE SHSE:600332 SHSE:600998 TSE:7459 OSTO:ASKER MIL:AMP SHSE:600511

Other Exchanges EDA:Germany

Address Parc d\'Activites La Poudrette-Lamartine, 4/6, rue du Dauphine, Vaulx-en-Velin, FRA, 69120

Website http://www.focalone.com

Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.

53GF Score

Get the complete analysis for FOCL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.08

Price

$4.52

GF Value

View FOCL Analysis

See EBIT data for all stocks →